
BriaCell Therapeutics fell 54.4% from $7.69 to $3.51, behind the S&P 500's +11.0%. Its worst day was Jan 14 (−55.5%), and its low came Jun 11 at $2.74.
Nov 18, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
BriaCell Therapeutics closed at its highest level of the year, 64.4% above where the year started.
+29.9% · S&P 500 +0.1%
Story events cover the past 12 months · Times ET
EPS of $-4.35 missed the $-3.28 estimate on $0.00 revenue (est. $2.1M).
−7.5% · S&P 500 −1.1%
BriaCell Therapeutics shares fell 22.4%, while the S&P 500 rose 0.5%.
−22.4% · S&P 500 +0.5%
Each Warrant is immediately exercisable, will entitle the holder to purchase one common share at an exercise price of $6.93 per share and will expire five years from the date of issuance.
−55.5%, the year's worst day · S&P 500 −0.5%
EPS of $-2.58 beat the $-4.84 estimate on $0.00 revenue (est. $840,000.00).
+13.9% · S&P 500 −0.1%
BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancerBria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, is designed with
−25.4% · S&P 500 −1.2%
EPS of $-0.99 was reported on $0.00 revenue.
−6.2% · S&P 500 −1.6%
BriaCell Therapeutics shares rose 18.5%, while the S&P 500 rose 0.9%.
+18.5% · S&P 500 +0.9%
EPS of $-1.50 was reported on $0.00 revenue.
−5.4% · S&P 500 −0.4%
BriaCell Therapeutics shares rose 20.8%, while the S&P 500 rose 0.3%.
+20.8% · S&P 500 +0.3%
Where it ended: a close of $3.51 on Nov 17, 2026. Up next: Q1 2027 earnings on Dec 10, 2026.
Nothing in the past 12 months.
All BCTX analyst actionsNothing in the past 12 months.
All BCTX dividend historyChart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for BCTX and SPY from Benzinga historical bars. Not investment advice.